AR057414A1 - Derivados de prostaglandina - Google Patents
Derivados de prostaglandinaInfo
- Publication number
- AR057414A1 AR057414A1 ARP060102785A ARP060102785A AR057414A1 AR 057414 A1 AR057414 A1 AR 057414A1 AR P060102785 A ARP060102785 A AR P060102785A AR P060102785 A ARP060102785 A AR P060102785A AR 057414 A1 AR057414 A1 AR 057414A1
- Authority
- AR
- Argentina
- Prior art keywords
- integer
- ono2
- alkyl
- defined above
- group
- Prior art date
Links
- 229910004679 ONO2 Inorganic materials 0.000 abstract 6
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
- 150000002828 nitro derivatives Chemical class 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- -1 prostaglandin amides Chemical class 0.000 abstract 1
- 150000003180 prostaglandins Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen nitroderivados de amidas de prostaglandina que tienen mejor actividad farmacologica y mayor tolerabilidad. Se pueden emplear para el tratamiento de glaucoma y la hipertension ocular. Reivindicacion 1: Un compuesto de formula general R- X-(B)m-Y-ONO2 o su sal o estereoisomero farmacéuticamente aceptable en la que R es el residuo de prostaglandina de formula (1): en la que el símbolo - - - representa un enlace sencillo o un doble enlace; L se selecciona entre los compuestos del grupo (2): X es -NR1-, en el que R1 = H o alquilo C1-6; m es un entero igual a 0 o 1; B es un radical de la formula -CH(R1')COO-, en la que R1' es H, alquilo C1-10 recto o ramificado, opcionalmente sustituido con uno o más de los sustituyentes seleccionados entre el grupo que consiste en: -OH, -COOH, -CONH2, -NH2, -SH, -SCH3, (3) Y es un radical bivalente que tiene el siguiente significado: a) -alquileno C1-20 recto o ramificado, opcionalmente sustituido con uno o más de los sustituyentes seleccionados entre el grupo que consiste en: átomos de halogeno, hidroxi, -ONO2 o T, en el que T es -OC(O)(alquilo C1-10)-ONO2 o -O(alquilo C1-10)-ONO2; - cicloalquileno con 5 a 7 átomos de carbono en el anillo cicloalquileno, estando el anillo opcionalmente sustituido con cadenas laterales T1, en las que T1 es alquilo C1-10 recto o ramificado; b) (4); c) (5) en las que n es un entero entre 0 y 20, y n1 es un entero entre 1 y 20; d) (6) en la que X1 = -OCO- o -COO- y R2 es H o CH3; Z es -(CH2)n1- o el radicalbivalente anteriormente definido bajo b); n1 es tal como se definio anteriormente y n2 es un entero entre 0 y 2; e) (7) en la que Y1 es -CH2-CH2-(CH2)n2- o -CH=CH-(CH2)n2-; Z, n1, n2, R2 y X1 son tal como se definio anteriormente; con la salvedad que: i) cuando Y se selecciona entre los radicales bivalentes mencionados bajo b)-e), entonces el grupo -ONO2 terminal está unido a -(CH2)n2; ii) cuando y se selecciona entre los radicales bivalentes mencionados bajo ")o c) y n = 0, entonces m = 1; iii) cuando y se selecciona entre los radicales bivalentes mencionados bajo d) o e), entonces m = 1; g) (8), (9) en la que X2 es -O- o -S-, n3 es un entero entre 1 y 6, R2 es tal como se definio anteriormente; h) (10) en la que n4 es un entero entre 0 y 10; n5 es un entero ente 1 y 10; R4, R5, R6, R7 son iguales o diferentes y son H o alquilo C1-4 recto o ramificado; en los que el grupo -ONO2 está unido a >[C]n5 en la que n5 es tal como se definio anteriormente; Y2 es un anillo heterocíclico saturado, insaturado o aromático de 5 o 6 miembros, que contiene uno o más heteroátomos seleccionados entre nitrogeno, oxígeno, azufre, y se selecciona entre (Y1), (Y2), (Y3), (Y4), (Y5), (Y6), (Y7), (Y8), (Y9), (Y10), (Y11), (Y12), (Y13).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69638305P | 2005-06-29 | 2005-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057414A1 true AR057414A1 (es) | 2007-12-05 |
Family
ID=37309319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102785A AR057414A1 (es) | 2005-06-29 | 2006-06-28 | Derivados de prostaglandina |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7718656B2 (es) |
| EP (1) | EP1899295A2 (es) |
| JP (1) | JP2009501150A (es) |
| AR (1) | AR057414A1 (es) |
| CA (1) | CA2613748A1 (es) |
| GT (1) | GT200600277A (es) |
| NL (1) | NL1032046C2 (es) |
| PE (1) | PE20070120A1 (es) |
| TW (1) | TW200730179A (es) |
| UY (1) | UY29627A1 (es) |
| WO (1) | WO2007000641A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100099729A1 (en) * | 2007-02-05 | 2010-04-22 | Nicox S.A. | Nitric oxide donor compounds |
| US7960379B2 (en) | 2008-03-14 | 2011-06-14 | Allergan, Inc. | Therapeutic compounds |
| AR076731A1 (es) | 2008-05-09 | 2011-07-06 | Pfizer | Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas |
| WO2013126156A1 (en) * | 2012-02-22 | 2013-08-29 | Bausch & Lomb Incorporated | Nitric oxide donating selective glucocorticoid receptor agonist compounds and ophthalmic compositions |
| EP2826491A1 (en) | 2013-07-15 | 2015-01-21 | Nicox Science Ireland | Ophthalmic compositions containing a nitric oxide donor |
| CN107106573A (zh) * | 2014-10-15 | 2017-08-29 | 诺华股份有限公司 | 用于治疗青光眼和眼压过高的前列腺素偶联物和衍生物 |
| WO2016155906A1 (en) * | 2015-03-31 | 2016-10-06 | Nicox S.A. | Nitric oxide donating derivatives of fluprostenol |
| US10047047B2 (en) | 2015-03-31 | 2018-08-14 | Nicox S.A. | Nitric oxide donating derivatives of latanoprost free acid |
| EP3088388A1 (en) | 2015-04-30 | 2016-11-02 | NicOx S.A. | Nitric oxide donating derivatives of prostaglandins |
| CA3043000A1 (en) | 2016-11-08 | 2018-05-17 | Bausch & Lomb Incorporated | Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma |
| KR102069205B1 (ko) * | 2017-08-09 | 2020-01-22 | 연성정밀화학(주) | 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3922293A (en) * | 1971-12-30 | 1975-11-25 | Upjohn Co | Prostaglandin F-type 9-monoacylates |
| US4952581A (en) * | 1987-04-03 | 1990-08-28 | The Trustees Of Columbia University In The City Of New York | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure |
| EP0569046B1 (en) * | 1988-09-06 | 2002-11-13 | Pharmacia Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| AU674038B2 (en) * | 1992-10-13 | 1996-12-05 | Alcon Laboratories, Inc. | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma |
| US5625083A (en) * | 1995-06-02 | 1997-04-29 | Bezuglov; Vladimir V. | Dinitroglycerol esters of unsaturated fatty acids and prostaglandins |
| IT1295694B1 (it) * | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
| IT1292377B1 (it) * | 1997-06-19 | 1999-02-08 | Nicox Sa | Composizioni farmaceutiche a base di prostaglandine |
| US6417228B1 (en) * | 1998-11-02 | 2002-07-09 | Alcon Manufacturing, Ltd.. | 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension |
| US7186744B2 (en) | 2003-11-13 | 2007-03-06 | Allergan, Inc. | Prostamides for the treatment of glaucoma and related diseases |
| ME02433B (me) * | 2004-01-05 | 2016-09-20 | Nicox Sa | Nitrooksiderivati prostaglandina |
-
2006
- 2006-06-19 CA CA002613748A patent/CA2613748A1/en not_active Abandoned
- 2006-06-19 WO PCT/IB2006/001727 patent/WO2007000641A2/en not_active Application Discontinuation
- 2006-06-19 JP JP2008518996A patent/JP2009501150A/ja not_active Withdrawn
- 2006-06-19 EP EP06765590A patent/EP1899295A2/en not_active Withdrawn
- 2006-06-22 NL NL1032046A patent/NL1032046C2/nl not_active IP Right Cessation
- 2006-06-27 UY UY29627A patent/UY29627A1/es not_active Application Discontinuation
- 2006-06-27 PE PE2006000747A patent/PE20070120A1/es not_active Application Discontinuation
- 2006-06-28 TW TW095123347A patent/TW200730179A/zh unknown
- 2006-06-28 AR ARP060102785A patent/AR057414A1/es unknown
- 2006-06-28 GT GT200600277A patent/GT200600277A/es unknown
- 2006-06-28 US US11/478,129 patent/US7718656B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7718656B2 (en) | 2010-05-18 |
| PE20070120A1 (es) | 2007-02-09 |
| WO2007000641A8 (en) | 2008-03-06 |
| WO2007000641A2 (en) | 2007-01-04 |
| EP1899295A2 (en) | 2008-03-19 |
| GT200600277A (es) | 2007-02-14 |
| US20090062296A1 (en) | 2009-03-05 |
| JP2009501150A (ja) | 2009-01-15 |
| UY29627A1 (es) | 2007-01-31 |
| NL1032046C2 (nl) | 2007-04-24 |
| NL1032046A1 (nl) | 2007-01-02 |
| TW200730179A (en) | 2007-08-16 |
| CA2613748A1 (en) | 2007-01-04 |
| WO2007000641A3 (en) | 2007-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057414A1 (es) | Derivados de prostaglandina | |
| AR047081A1 (es) | Derivados de prostaglandinas, metodos para su preparacion, composiciones farmaceuticas que las contienen y su uso en el tratamiento del glaucoma y de la hipertension ocular. | |
| RU2010133903A (ru) | Способ и промежуточные соединения для получения производных 5-бифенил-4-ил-2-метилпентановой кислоты | |
| PE20070135A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
| AR056868A1 (es) | Nitrooxi derivados de esteroides, composiciones farmaceuticas y su uso para tratar trastornos de la piel o de la membrana mucosa | |
| AR072233A1 (es) | Derivados de acido lipoico y composiciones farmaceuticas que los contienen y metodos para tratar una enfermedad | |
| AR045145A1 (es) | Nitro-oxi derivados bloqueadores del receptor de angiotensina ii | |
| CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
| PE20011184A1 (es) | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa | |
| AR060545A1 (es) | Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas | |
| AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
| ES2525353T3 (es) | Derivado de espiroimidazolona | |
| RU2016151705A (ru) | Улучшенное обесцвечивание окрашенных кератиновых волокон | |
| CO5690576A2 (es) | Profarmacos de los inhibidores de bomba de protones | |
| AR027074A1 (es) | Derivados de nitrilo como inhibidores de catepsina k | |
| AR126076A1 (es) | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar | |
| AR075701A1 (es) | Composicion de control de plagas | |
| PE20060557A1 (es) | Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas como antagonistas de los receptores trpv1 | |
| CO2018010787A2 (es) | Compuesto de griseofulvina | |
| AR053340A1 (es) | Derivados de trifluormetilbenzamida y sus usos terapeuticos | |
| MX2011011281A (es) | Compuesto de carbinol que tiene un enlazante heterociclico. | |
| ECSP10010380A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR061598A1 (es) | Nitroderivados heterociclicos como antagonistas de receptor de endotelina | |
| AR004264A1 (es) | Compuesto beta-amino ester de alcoholes perfumados para su uso en composiciones para lavado de ropa y limpieza de superficies duras, proceso depreparacion, metodo de uso. | |
| AR057870A1 (es) | Nitroderivados inhibidores de renina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |